Integrated BioPharma reports results for the quarter and fiscal year ended June 30, 2024

HILLSIDE, NJ / ACCESSWIRE / September 20, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the “Company” or “INBP”) reports its financial results for the quarter and fiscal year ended June 30, 2024.

Revenue for the quarter ended June 30, 2024 was $12.7 million compared to $13.0 million for the quarter ended June 30, 2023, a decrease of $0.3 million, or 2.3%. The Company generated operating income of approximately $402,000 and $79,000 for the quarters ended June 30, 2024 and 2023, respectively.